Results 181 to 190 of about 23,408 (219)
Some of the next articles are maybe not open access.

Anesthesia and Monoamine Oxidase Inhibitors

JAMA: The Journal of the American Medical Association, 1989
To the Editor.— I wish to register my strong disagreement with your consultants Drs Hirshman and Lindeman 1 and their assertion that it is safe to administer an elective anesthetic to a patient receiving monoamine oxidase inhibitors. 1 I believe that theirs is a minority viewpoint.
openaire   +2 more sources

Comparative effects of monoamine oxidase inhibitors on monoamine oxidase and diamine oxidase

Biochemical Pharmacology, 1960
Abstract The effect of several monoamine oxidase (MAO) inhibitors and related compounds on guinea pig liver MAO and diamine oxidase (DAO) was examined in vitro and after administration to animals. The results showed that the MAO inhibitors possessing the hydrazine moiety inhibited both MAO and DAO, while two phenyl cyclo propylamine MAO inhibitors ...
P A, SHORE, V H, COHN
openaire   +2 more sources

Monoamine Oxidase Inhibitors

Drugs & Aging, 1998
Monoamine oxidase inhibitors (MAOIs) are mainly used in psychiatry for the treatment of depressive disorders and in neurology for the treatment of Parkinson's disease. While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine ...
H P, Volz, C H, Gleiter
openaire   +2 more sources

Monoamine Oxidase Inhibitors

Anesthesia & Analgesia, 1985
Adverse cardiovascular responses to anesthesia during either electroconvulsive therapy (ECT) or elective surgical procedures were evaluated in 27 patients maintained on chronic (3 months-3 yr) monoamine oxidase inhibitor (MAOI) therapy. Changes in blood pressure and heart rate in study patients (n = 22 ECTs in 13 patients) undergoing ECT were not ...
A R, el-Ganzouri   +3 more
openaire   +2 more sources

Monoamine Oxidase Inhibitors and Neuroprotection

American Journal of Therapeutics, 2012
Monoamine oxidase inhibitors have been available for more than 50 years, initially developed as antidepressants but currently used in a variety of psychiatric and neurological conditions. There has been a recent surge of interest in monoamine oxidase inhibitors because of their reported neuroprotective and/or neurorescue properties.
Saleem K, Al-Nuaimi   +2 more
openaire   +2 more sources

Monoamine Oxidase Inhibitors

Archives of General Psychiatry, 1979
Data from double-blind, placebo-controlled trials of the monoamine oxidase (MAO) inhibitors show that phenelzine is clearly effective in neurotic or atypical depressives, but the findings concerning its effect in endogenous depressives are inconclusive.
F, Quitkin, A, Rifkin, D F, Klein
openaire   +2 more sources

Monoamine Oxidase Inhibitors

Drug Safety, 1996
After initial enthusiasm, the use of monoamine oxidase inhibitors (MAOIs) has been limited by the wide range of MAOI-drug and MAOI-food interactions that are possible, particularly with sympathomimetic medications or tyramine-containing foods, resulting in hypertensive reactions.
M G, Livingston, H M, Livingston
openaire   +2 more sources

Monoamine Oxidase Inhibitors

Journal of Clinical Psychopharmacology, 1983
Dangers of adverse effects with MAOIs have been exaggerated, the most serious being hypertensive interactions with cheeses, yeast extracts, certain alcoholic beverages, broad bean pods, certain meats, and foods that are unfresh or overripe. Some adverse reactions involving MAOI-diet interactions were likely due to migraine headache, consumption of ...
openaire   +2 more sources

Monoamine Oxidase Inhibitors

Journal of Pharmaceutical Sciences, 1972
openaire   +2 more sources

Home - About - Disclaimer - Privacy